scispace - formally typeset
Search or ask a question
Institution

Applied Biosystems

About: Applied Biosystems is a based out in . It is known for research contribution in the topics: Mass spectrometry & Nucleic acid. The organization has 1521 authors who have published 1579 publications receiving 285423 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: Diminished expression of metallothioneins featured strongly among these and suggests a possible role for this family as tumour suppressors in PTC, and numerous transcripts never previously implicated in thyroid carcinogenesis are identified.
Abstract: The most common sub-variant of papillary thyroid carcinoma (PTC) is the so-called follicular variant (FVPTC), which is a particularly problematic lesion and can be challenging from a diagnostic viewpoint even in resected lesions. Although fine needle aspiration cytology is very useful in the diagnosis of PTC, its accuracy and utility would be greatly facilitated by the development of specific markers for PTC and its common variants. We used the recently developed Applied Biosystems 1700 microarray system to interrogate a series of 11 benign thyroid lesions and conditions and 14 samples of PTC (six with classic morphology and eight with follicular variant morphology). TaqMan® reverse transcriptase-polymerase chain reaction was used to validate the expression portfolios of 50 selected transcripts. Our data corroborates potential biomarkers previously identified in the literature, such as LGALS3, S100A11, LYN, BAX, and cluster of differentiation 44 (CD44). However, we have also identified numerous transcripts never previously implicated in thyroid carcinogenesis, and many of which are not represented on other microarray platforms. Diminished expression of metallothioneins featured strongly among these and suggests a possible role for this family as tumour suppressors in PTC. Fifteen transcripts were significantly associated with FVPTC morphology. Surprisingly, these genes were associated with an extremely narrow repertoire of functions, including the major histocompatibility complex and cathepsin families.

52 citations

Patent
14 Sep 2000
TL;DR: In this paper, water-soluble, red-emitting fluorescent rhodamine dyes and fluorescent energy-transfer dye pairs, as well as labeled conjugates comprising the same and methods for their use are presented.
Abstract: The present invention provides novel, water-soluble, red-emitting fluorescent rhodamine dyes and red-emitting fluorescent energy-transfer dye pairs, as well as labeled conjugates comprising the same and methods for their use. The dyes, energy-transfer dye pairs and labeled conjugates are useful in a variety of aqueous-based applications, particularly in assays involving staining of cells, protein binding, and/or analysis of nucleic acids, such as hybridization assays and nucleic acid sequencing.

52 citations

Patent
08 Dec 1999
TL;DR: In this paper, a method for the detection, identification and quantification of nucleic acids which are electrostatically immobilized to matrices using non-nucleotide probes which sequence specifically hybridize to one or more target sequences of the nucleic acid but do not otherwise substantially interact with the matrix is presented.
Abstract: This invention pertains to methods, kits and compositions suitable for the detection, identification and/or quantitation of nucleic acids which are electrostatically immobilized to matrices using non-nucleotide probes which sequence specifically hybridize to one or more target sequences of the nucleic acid but do not otherwise substantially interact with the matrix. Once the nucleic acid is immobilized, the detectable non-nucleotide probe/target sequence complex, formed before or after the immobilization of the nucleic acid, can be detected, identified or quantitated under a wide range of assay conditions as a means to detect, identify or quantitate the target sequence in the sample. Because it is reversibly bound, the non-nucleotide probe/target sequence can optionally be removed from the matrix for detecting, identifying or quantitating the target sequence in the sample. Because the non-nucleotide probe/target sequence is protected against degradation, it is another advantage of this invention that the sample can be treated with enzymes which degrade sample components, either before or after the nucleic acid is bound to the matrix, in order to “clean up” the sample (e.g. a complex biological sample such as a cell lysate) and thereby improve the detection, identification or quantitation of the target sequence in the sample. The methods, kits and compositions of this invention are therefore particularly well suited for the analysis, and particularly single point mutation analysis, in a particle assay, in an array assay, in a nuclease digestion/protection assay and/or in a line assay format. When utilized in combination with non-nucleotide “Beacon” probes, the invention is particularly well suited for use in a self-indicating assay format.

51 citations

Journal ArticleDOI
19 Oct 1984-Science
TL;DR: The techniques used for the characterization of protein and peptide structure have undergone great changes that have improved the speed, reliability, and applicability of the process, and has made possible the structural analysis of a wide variety of scarce but important compounds.
Abstract: The techniques used for the characterization of protein and peptide structure have undergone great changes that have improved the speed, reliability, and applicability of the process. High-performance liquid chromatography and gel electrophoresis have made the purification of proteins and peptides a routine procedure, even when the compound of interest is a minor component of a complex biological mixture. The chemistry and instrumentation used in amino acid analysis and amino acid sequencing now permit the analysis of as little as 5 to 50 picomoles of samples. This represents an increase in sensitivity of more than a thousandfold over the last 10 years and has made possible the structural analysis of a wide variety of scarce but important compounds.

51 citations

Patent
13 Dec 2011
TL;DR: In this article, the synthesis of capped/tagged RNA, methods of use and kits providing same are contemplated, and the ability to isolate and purify capped RNA results in improved transcription and translation and provides a tool for identifying RNA-protein interactions.
Abstract: The synthesis of capped/tagged RNA, methods of use and kits providing same are contemplated. Tagged RNA permits isolation of RNA transcripts in vitro. The ability to isolate and purify capped RNA results in improved transcription and translation and provides a tool for identifying RNA-protein interactions. Such capped RNA finds use in therapeutic applications, diagnosis and prognosis and in the treatment of cancers and HIV.

51 citations


Authors

Showing all 1521 results

NameH-indexPapersCitations
Richard A. Gibbs172889249708
Friedrich C. Luft113109547619
Alexander N. Glazer7120821068
Vineet Bafna6823642574
Kevin R. Coombes6330823592
Darryl J. Pappin6117029409
Mark D. Johnson6028916103
György Marko-Varga5640912600
Paul Thomas5612844810
Gerald Zon5525611126
Michael W. Hunkapiller5113029756
Bjarni V. Halldorsson5114513180
David H. Hawke501579824
Ellson Y. Chen507128836
Sridhar Hannenhalli4916221959
Network Information
Related Institutions (5)
Genentech
17.1K papers, 1.4M citations

88% related

National Institutes of Health
297.8K papers, 21.3M citations

86% related

Scripps Research Institute
32.8K papers, 2.9M citations

86% related

Hoffmann-La Roche
43K papers, 1.6M citations

85% related

Wellcome Trust Sanger Institute
9.6K papers, 1.2M citations

85% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20182
20171
20164
20152
20147
201313